Upgrades:
AllianceBernstein (NYSE:AB) was upgraded by investment analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued on Monday, The Fly reports. The brokerage presently has a $54.50 target price on the asset manager’s stock, up from their prior target price of $44.00. Citigroup’s price objective points to a potential upside of 12.91% from the company’s current price.
Several other equities research analysts also recently
issued reports on the stock. Sanford C. Bernstein downgraded shares of
AllianceBernstein from a “buy” rating to a “neutral” rating in a research
report on Friday, April 9th. Keefe, Bruyette & Woods restated a “market
perform” rating and set a $42.00 target price on shares of AllianceBernstein in
a report on Tuesday, April 13th. Zacks Investment Research cut shares of
AllianceBernstein from a “buy” rating to a “hold” rating in a report on
Tuesday, July 27th. Finally, Bank of America restated a “neutral” rating and
set a $42.00 target price on shares of AllianceBernstein in a report on
Thursday, April 15th. Six equities research analysts have rated the stock with
a hold rating and one has given a buy rating to the stock. AllianceBernstein
currently has an average rating of “Hold” and a consensus price target of
$44.36. Read
more …
Welltower (NYSE:WELL) was upgraded by equities research analysts at Berenberg Bank from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has a $100.00 price objective on the real estate investment trust's stock. Berenberg Bank's target price indicates a potential upside of 15.92% from the stock's previous close.
Other equities analysts also recently issued research
reports about the company. Wells Fargo & Company boosted their price target
on Welltower from $78.00 to $89.00 and gave the stock an "equal
weight" rating in a research report on Friday, July 23rd. Mizuho began
coverage on Welltower in a research report on Wednesday, July 14th. They set a
"neutral" rating and a $68.00 price target on the stock. Morgan Stanley
boosted their price target on Welltower from $79.00 to $86.00 and gave the
stock an "overweight" rating in a research report on Monday, July
26th. Capital One Financial raised Welltower from an "equal weight"
rating to an "overweight" rating in a research report on Friday, May
21st. Finally, Wolfe Research began coverage on Welltower in a research report
on Monday, June 14th. They set an "outperform" rating and a $94.00
price target on the stock. Eight research analysts have rated the stock with a
hold rating, eleven have issued a buy rating and one has issued a strong buy
rating to the stock. The stock currently has a consensus rating of
"Buy" and a consensus price target of $79.67. Read
more …
Simon Property Group (NYSE:SPG) was upgraded by equities researchers at Bank of America from a "neutral" rating to a "buy" rating in a note issued to investors on Wednesday, The Fly reports.
Several other brokerages have also recently weighed in on
SPG. Truist Securities boosted their price objective on Simon Property Group
from $102.00 to $130.00 and gave the stock a "hold" rating in a
report on Wednesday, June 23rd. UBS Group assumed coverage on Simon Property Group
in a report on Thursday, June 3rd. They set a "neutral" rating and a
$135.00 price objective for the company. BMO Capital Markets reissued a
"hold" rating on shares of Simon Property Group in a report on
Thursday, May 20th. Truist upped their price target on Simon Property Group
from $102.00 to $130.00 and gave the company a "hold" rating in a
research note on Wednesday, June 23rd. Finally, Stifel Nicolaus raised Simon
Property Group from a "hold" rating to a "buy" rating and
upped their price target for the company from $125.00 to $132.00 in a research
note on Monday, July 19th. One research analyst has rated the stock with a sell
rating, ten have assigned a hold rating and nine have issued a buy rating to
the company. Simon Property Group has an average rating of "Hold" and
an average price target of $128.13. Read
more …
Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at DNB Markets from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, The Fly reports.
NVO has been the topic of a number of other reports.
Barclays reiterated an “overweight” rating on shares of Novo Nordisk A/S in a
report on Monday, July 19th. Deutsche Bank Aktiengesellschaft reiterated a
“buy” rating on shares of Novo Nordisk A/S in a report on Tuesday. Finally,
Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell”
rating to a “hold” rating and set a $91.00 price target on the stock in a
report on Tuesday, July 13th. Two investment analysts have rated the stock with
a sell rating, four have given a hold rating and five have issued a buy rating
to the stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and a
consensus price target of $91.00. Read
more …
Eli Lilly and (NYSE:LLY) was upgraded by analysts at DZ Bank from a "hold" rating to a "buy" rating in a report issued on Thursday, Briefing.com reports. The firm presently has a $288.00 price objective on the stock. DZ Bank's price objective would suggest a potential upside of 9.73% from the stock's current price.
Several other equities research analysts also recently
issued reports on LLY. Morgan Stanley raised their target price on shares of
Eli Lilly and from $207.00 to $275.00 and gave the company an
"overweight" rating in a research note on Wednesday. The Goldman
Sachs Group raised their target price on shares of Eli Lilly and from $252.00
to $270.00 and gave the company a "conviction-buy" rating in a
research note on Monday, June 14th. Cowen raised their target price on shares
of Eli Lilly and from $235.00 to $250.00 and gave the company an
"outperform" rating in a research note on Thursday, June 24th. Cantor
Fitzgerald raised their target price on shares of Eli Lilly and from $245.00 to
$300.00 and gave the company an "overweight" rating in a research
note on Thursday, June 24th. Finally, Zacks Investment Research downgraded
shares of Eli Lilly and from a "hold" rating to a "sell"
rating and set a $244.00 price objective for the company. in a research report
on Monday, July 19th. One research analyst has rated the stock with a sell
rating, two have assigned a hold rating, twelve have assigned a buy rating and
one has issued a strong buy rating to the company. The company has a consensus
rating of "Buy" and an average price target of $244.19. Read
more …
Walmart (NYSE:WMT) was upgraded by equities research analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating in a research report issued on Thursday, Briefing.com reports. The brokerage presently has a $165.00 price objective on the retailer’s stock, up from their previous price objective of $150.00. Wells Fargo & Company‘s price target suggests a potential upside of 15.51% from the stock’s previous close.
Other equities analysts have also issued research reports
about the company. Royal Bank of Canada upped their price target on Walmart
from $163.00 to $173.00 and gave the company an “outperform” rating in a
research note on Monday, May 24th. The Goldman Sachs Group reaffirmed a “buy”
rating and issued a $170.00 price target on shares of Walmart in a research
note on Tuesday, May 18th. Credit Suisse Group started coverage on Walmart in a
report on Wednesday, May 19th. They issued an “outperform” rating and a $150.00
price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their
price objective on Walmart from $165.00 to $181.00 and gave the company a “buy”
rating in a report on Wednesday, May 19th. Finally, Raymond James boosted their
price objective on Walmart from $155.00 to $165.00 and gave the company an
“outperform” rating in a report on Tuesday, May 25th. One equities research
analyst has rated the stock with a sell rating, three have assigned a hold
rating and twenty-two have issued a buy rating to the company. Walmart
currently has a consensus rating of “Buy” and an average price target of
$162.94. Read
more …
Eastman Chemical (NYSE:EMN) was upgraded by equities research analysts at Bank of America from a "neutral" rating to a "buy" rating in a research note issued to investors on Thursday, Briefing.com reports. The firm currently has a $140.00 price objective on the basic materials company's stock. Bank of America's price target would suggest a potential upside of 28.42% from the stock's current price.
A number of other equities research analysts also recently
issued reports on the stock. Scotiabank raised shares of Eastman Chemical from
a "sector perform" rating to a "sector outperform" rating
and set a $145.00 price target on the stock in a research note on Monday, June
21st. The Goldman Sachs Group raised shares of Eastman Chemical from a
"neutral" rating to a "buy" rating and set a $148.00 price
target on the stock in a research note on Tuesday, May 11th. Wells Fargo &
Company upped their price target on shares of Eastman Chemical from $130.00 to
$142.00 and gave the company an "overweight" rating in a research
note on Tuesday, June 22nd. Royal Bank of Canada reiterated a "sector
perform" rating and set a $109.44 price objective (down previously from
$119.00) on shares of Eastman Chemical in a research report on Tuesday, July
27th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective
on shares of Eastman Chemical from $132.00 to $140.00 and gave the company a
"buy" rating in a research report on Monday, June 14th. Four
investment analysts have rated the stock with a hold rating and eight have given
a buy rating to the stock. The stock currently has an average rating of
"Buy" and an average price target of $125.54. Read
more …
BP (NYSE:BP) was upgraded by research analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating in a report released on Friday, The Fly reports.
A number of other research analysts have also recently
issued reports on BP. Royal Bank of Canada restated a "sector
perform" rating on shares of BP in a report on Wednesday. HSBC set a
$23.76 price objective on shares of BP and gave the company a "hold"
rating in a report on Thursday, July 22nd. restated a "neutral"
rating and set a $70.00 price objective on shares of BP in a report on
Wednesday, June 30th. Societe Generale reaffirmed a "buy" rating on
shares of BP in a research note on Wednesday, April 28th. Finally, Mizuho
lifted their price target on shares of BP from $30.00 to $33.00 and gave the
company a "neutral" rating in a research note on Monday, May 17th.
Two investment analysts have rated the stock with a sell rating, ten have
assigned a hold rating and ten have given a buy rating to the company. BP has
an average rating of "Hold" and an average price target of $37.48. Read
more …
ViacomCBS (NASDAQ:VIAC) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday, The Fly reports. The firm currently has a $45.00 price target on the stock, up from their previous price target of $32.00. Deutsche Bank Aktiengesellschaft's target price suggests a potential upside of 8.30% from the company's current price. The analysts noted that the move was a valuation call.
Several other analysts also recently commented on VIAC.
lowered their target price on shares of ViacomCBS from $56.00 to $54.00 and set
a "buy" rating for the company in a report on Friday, May 21st. Wells
Fargo & Company upgraded shares of ViacomCBS from an
"underweight" rating to an "equal weight" rating and
decreased their price objective for the stock from $59.00 to $45.00 in a report
on Friday, May 7th. Barrington Research upgraded shares of ViacomCBS from a
"market perform" rating to an "outperform" rating and set a
$50.00 price objective for the company in a report on Monday, May 10th.
Macquarie upgraded shares of ViacomCBS from an "underperform" rating
to a "neutral" rating in a report on Thursday, May 6th. Finally,
Rosenblatt Securities decreased their price objective on shares of ViacomCBS
from $61.00 to $45.00 and set a "neutral" rating for the company in a
report on Wednesday, May 12th. Three research analysts have rated the stock
with a sell rating, eleven have assigned a hold rating and nine have issued a
buy rating to the stock. The company presently has an average rating of
"Hold" and a consensus price target of $49.13. Read
more …
Downgrades:
The Clorox (NYSE:CLX) was downgraded by research analysts at Atlantic Securities from an “overweight” rating to a “neutral” rating in a research note issued to investors on Wednesday, Briefing.com reports. They currently have a $150.00 price objective on the stock. Atlantic Securities’ target price indicates a potential downside of 8.57% from the company’s current price.
Several other equities analysts have also recently issued
reports on CLX. JPMorgan Chase & Co. lowered their price objective on The
Clorox from $205.00 to $196.00 and set a “neutral” rating on the stock in a
research report on Friday, April 16th. Argus decreased their target price on
shares of The Clorox from $230.00 to $206.00 and set a “buy” rating for the
company in a research note on Friday, May 21st. Credit Suisse Group decreased
their target price on shares of The Clorox from $205.00 to $185.00 and set a “neutral”
rating for the company in a research note on Monday, May 3rd. Barclays
reiterated a “sell” rating and set a $162.00 target price on shares of The
Clorox in a research note on Sunday, April 18th. Finally, DA Davidson reduced
their price objective on The Clorox from $189.00 to $177.00 and set a “neutral”
rating for the company in a research note on Monday, May 3rd. Four analysts
have rated the stock with a sell rating, eleven have assigned a hold rating and
three have issued a buy rating to the stock. The Clorox presently has an
average rating of “Hold” and a consensus target price of $198.06. Read
more …
Chevron (NYSE:CVX) was downgraded by DZ Bank from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Briefing.com reports. They currently have a $110.00 price objective on the oil and gas company’s stock. DZ Bank’s price target suggests a potential upside of 7.21% from the stock’s current price.
Several other equities analysts have also weighed in on CVX.
The Goldman Sachs Group reiterated a “neutral” rating and issued a $113.00
target price (down from $117.00) on shares of Chevron in a report on Tuesday,
April 13th. Redburn Partners upgraded shares of Chevron from a “neutral” rating
to a “buy” rating in a report on Thursday, July 22nd. Truist Securities upped
their price objective on shares of Chevron from $130.00 to $144.00 and gave the
stock a “buy” rating in a report on Thursday, July 1st. Raymond James upped
their price objective on shares of Chevron from $120.00 to $125.00 and gave the
stock an “outperform” rating in a report on Monday. Finally, BMO Capital
Markets started coverage on shares of Chevron in a report on Monday, July 12th.
They issued an “outperform” rating and a $123.00 price objective on the stock.
Eleven analysts have rated the stock with a hold rating and sixteen have issued
a buy rating to the company’s stock. The company presently has an average
rating of “Buy” and a consensus price target of $117.19. Read
more …
Omega Healthcare Investors (NYSE:OHI) was downgraded by analysts at Capital One Financial from an "overweight" rating to an "equal weight" rating in a research report issued to clients and investors on Wednesday, Briefing.com reports. They presently have a $38.00 target price on the real estate investment trust's stock. Capital One Financial's price objective points to a potential upside of 9.83% from the stock's current price.
OHI has been the subject of a number of other research
reports. Zacks Investment Research cut shares of Omega Healthcare Investors
from a "hold" rating to a "sell" rating in a research
report on Wednesday, July 14th. Wolfe Research started coverage on shares of
Omega Healthcare Investors in a research report on Monday, June 14th. They set
a "peer perform" rating and a $43.00 target price for the company.
Scotiabank cut shares of Omega Healthcare Investors from a "sector
outperform" rating to a "sector perform" rating and dropped
their target price for the stock from $41.00 to $39.00 in a research report on
Thursday, June 17th. They noted that the move was a valuation call. Mizuho
reiterated a "neutral" rating and set a $39.00 target price on shares
of Omega Healthcare Investors in a research report on Wednesday, July 14th.
Finally, Wells Fargo & Company raised their price objective on shares of
Omega Healthcare Investors from $39.00 to $43.00 and gave the company an
"overweight" rating in a research report on Friday, July 23rd. One
equities research analyst has rated the stock with a sell rating, three have
given a hold rating and five have given a buy rating to the company. The
company has a consensus rating of "Hold" and an average price target
of $39.23. Read
more …
Pinnacle West Capital (NYSE:PNW) was downgraded by investment analysts at KeyCorp from a "sector weight" rating to an "underweight" rating in a report issued on Wednesday, Briefing.com reports. They presently have a $72.00 price objective on the utilities provider's stock. KeyCorp's target price would indicate a potential downside of 11.09% from the company's previous close.
PNW has been the subject of several other reports. Credit
Suisse Group boosted their target price on Pinnacle West Capital from $81.00 to
$91.00 and gave the stock a "neutral" rating in a research note on
Monday, May 3rd. Wells Fargo & Company reissued an "equal weight"
rating and set a $94.00 target price (up from $92.00) on shares of Pinnacle
West Capital in a research note on Monday, May 17th. Barclays cut Pinnacle West
Capital from an "overweight" rating to an "equal weight"
rating and lowered their target price for the stock from $100.00 to $84.00 in a
research note on Wednesday. Siebert Williams Shank reissued a "buy"
rating and set a $84.48 target price (down from $92.00) on shares of Pinnacle
West Capital in a research note on Monday, July 26th. Finally, Morgan Stanley
lifted their price target on Pinnacle West Capital from $81.00 to $83.00 and
gave the stock an "equal weight" rating in a report on Monday, June
21st. Two equities research analysts have rated the stock with a sell rating,
seven have given a hold rating and two have issued a buy rating to the stock.
Pinnacle West Capital currently has a consensus rating of "Hold" and
an average target price of $84.45. Read
more …
American Water Works (NYSE:AWK) was downgraded by investment analysts at Janney Montgomery Scott from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Wednesday, The Fly reports. They presently have a $181.00 price objective on the utilities provider's stock, up from their prior price objective of $159.00. Janney Montgomery Scott's price target would indicate a potential upside of 3.25% from the stock's current price.
Other equities research analysts have also recently issued
research reports about the stock. Barclays boosted their target price on shares
of American Water Works from $170.00 to $174.00 and gave the company an
"equal weight" rating in a research report on Thursday, July 15th.
Argus reissued a "hold" rating on shares of American Water Works in a
research report on Tuesday, May 18th. Five research analysts have rated the
stock with a hold rating and four have issued a buy rating to the company's
stock. American Water Works presently has an average rating of "Hold"
and an average target price of $174.40. Read
more …
BAE Systems (OTCMKTS:BAESY) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Wednesday, The Fly reports.
Other equities analysts have also recently issued research
reports about the company. UBS Group restated a “neutral” rating on shares of
BAE Systems in a report on Monday. BNP Paribas restated a “neutral” rating on
shares of BAE Systems in a report on Thursday, April 15th. Morgan Stanley
restated an “overweight” rating on shares of BAE Systems in a report on Friday,
July 30th. Societe Generale restated a “buy” rating on shares of BAE Systems in
a report on Tuesday, May 25th. Finally, Zacks Investment Research upgraded BAE
Systems from a “sell” rating to a “hold” rating in a report on Tuesday, May
18th. Five equities research analysts have rated the stock with a hold rating
and eight have issued a buy rating to the company’s stock. The company
currently has a consensus rating of “Buy” and an average target price of
$31.00. Read
more …
Thomson Reuters (NYSE:TRI) (TSE:TRI) was downgraded by research analysts at Canaccord Genuity from a “buy” rating to a “hold” rating in a research note issued on Friday, The Fly reports.
A number of other research analysts have also issued reports
on TRI. National Bank Financial lowered Thomson Reuters from an “outperform”
rating to a “sector perform” rating in a research report on Friday. Morgan
Stanley lifted their target price on Thomson Reuters from $92.00 to $96.00 and
gave the company an “equal weight” rating in a research note on Wednesday, May
5th. Royal Bank of Canada boosted their price objective on Thomson Reuters from
$104.00 to $112.00 and gave the stock an “outperform” rating in a research note
on Friday, July 30th. They noted that the move was a valuation call. TD
Securities boosted their price objective on Thomson Reuters from C$130.00 to
C$135.00 and gave the stock a “buy” rating in a research note on Thursday, July
15th. Finally, CIBC boosted their price objective on Thomson Reuters from
$95.00 to $102.00 and gave the stock a “neutral” rating in a research note on
Monday, May 10th. One investment analyst has rated the stock with a sell
rating, five have given a hold rating and four have issued a buy rating to the
company’s stock. Thomson Reuters currently has a consensus rating of “Hold” and
a consensus target price of $111.60. Read
more …
Cardinal Health (NYSE:CAH) was downgraded by Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research report issued on Friday, PriceTargets.com reports. They presently have a $51.00 target price on the stock, down from their previous target price of $62.00. Deutsche Bank Aktiengesellschaft’s target price suggests a potential downside of 0.39% from the company’s previous close.
Several other equities research analysts have also recently
weighed in on the company. Bank of America cut Cardinal Health from a “buy”
rating to an “underperform” rating and dropped their target price for the
company from $69.00 to $56.00 in a report on Thursday. Citigroup cut Cardinal
Health from a “buy” rating to an “underperform” rating and dropped their target
price for the company from $69.00 to $56.00 in a report on Thursday. They noted
that the move was a valuation call. Finally, Robert W. Baird restated a
“neutral” rating and set a $64.00 target price (down from $66.00) on shares of
Cardinal Health in a report on Monday, May 17th. Two investment analysts have
rated the stock with a sell rating, four have given a hold rating and three
have issued a buy rating to the company’s stock. Cardinal Health presently has
an average rating of “Hold” and an average target price of $58.89. Read
more …
Parker-Hannifin (NYSE:PH) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating in a research report issued on Friday, Analyst Price Targets reports. They presently have a $327.00 target price on the industrial products company’s stock, down from their prior target price of $366.00. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 8.50% from the stock’s current price.
PH has been the topic of a number of other reports. KeyCorp
upped their target price on shares of Parker-Hannifin from $350.00 to $375.00
and gave the company an “overweight” rating in a research report on Tuesday.
Argus upped their price target on Parker-Hannifin from $310.00 to $345.00 and
gave the company a “buy” rating in a research note on Wednesday, May 5th.
Barclays upped their price target on Parker-Hannifin from $330.00 to $340.00
and gave the company an “overweight” rating in a research note on Monday, May
3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $364.00 price
target on shares of Parker-Hannifin in a research note on Friday, July 2nd.
Finally, JPMorgan Chase & Co. upped their price target on Parker-Hannifin
from $283.00 to $288.00 and gave the company a “neutral” rating in a research
note on Wednesday, April 14th. They noted that the move was a valuation call.
Three equities research analysts have rated the stock with a hold rating and
eleven have given a buy rating to the company’s stock. The stock has a
consensus rating of “Buy” and a consensus target price of $334.64. Read
more …
Comments
Post a Comment